Curis Lifescien. Stock Price Today (NSE: CURIS)
Fundamental Score
Curis Lifescien. Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Curis Lifescien. share price today is ₹102.20, up +0.00% on NSE/BSE as of 1 August 2026. Curis Lifescien. (CURIS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹82.62 (Cr). The 52-week high for CURIS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 11.92x, CURIS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 21.80% and a debt-to-equity ratio of 0.46.
Curis Lifescien. Share Price Chart — NSE/BSE Historical Performance
Curis Lifescien. share price chart: 0.00% return over the past month. 52-week high ₹N/A, 52-week low ₹N/A.
AI Research Briefing
Powered by Gemini · 2026-08-01
Institutional flight and negative 5-year FCF render this low P/E SME pharma stock a classical value trap.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search in the last 2-4 weeks. Disclosures from May/June 2026 show FY26 net profit at ₹6.92 Cr (+11.4% YoY) on revenue of ₹60.63 Cr (+20.6% YoY), along with a 51% stake acquisition in Uninova Lifesciences for ₹20.66 lakh advance. However, the latest quarter YoY profit fell -31.66% on a -4.77% revenue drop, signaling operational deceleration.
CORE STORY (THE REAL GAME)
This is an SME pharma micro-cap listing relying on bolt-on acquisitions to sustain top-line growth while suffering from underlying cash conversion weakness. Institutional investors are dumping holding despite an optically low P/E multiple.
- Latest quarter YoY profit dropped -31.66% alongside a -4.77% revenue contraction.
- Significant institutional liquidation with DII down 5.06% and FII down 1.74%.
- No major catalysts found after live search in recent weeks.
- Successful earnings integration and revenue scale-up from 51%-acquired Uninova Lifesciences.
- Quarterly profit margin expansion and top-line growth turnaround.
- Working capital reduction leading to positive free cash flow generation.
- Micro/SME cap illiquidity risk with low daily traded volumes.
- Cumulative 5-year Free Cash Flow remains negative at ₹-12.53 Cr.
- Aggressive institutional dumping with combined FII/DII stake reduction over 6.8%.
Heavy institutional exit: DII stake reduced by 5.06% to 4.29% and FII down 1.74% to 1.19%, while promoter holding remains unchanged at 68.03%.
SME pharma micro-caps face severe working capital pressure and margin squeeze, driving capital toward scaled liquid mid-caps.
Acquired 51% stake in Uninova Lifesciences with ₹20.66 lakh initial advance paid; no major new order wins found after live search.
Poor quality — 5-year FCF stands negative at ₹-12.53 Cr despite reported accounting profits.
Dull short-to-medium term trajectory unless earnings rebound and working capital turns FCF positive.
Primary Thesis Risk
Micro-cap SME illiquidity combined with negative free cash flow conversion and sustained institutional dumping.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Curis Lifescien. Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Curis Lifescien. Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CURIS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (21.80%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (17.62%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 11.92 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Interest Coverage (9.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.03%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-31.66%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-12.53 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 6.99%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Curis Lifescien. vs Pharmaceuticals Peers
Peer Comparison -
Compare Curis Lifescien. with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
34.5/100 | ₹102.20₹102 | ₹82.62₹82.62 | 11.92Average 11.9 Average | 21.80%Excellent 21.80% Excellent | 21.25%Excellent 21.25% Excellent | 0.46Excellent 0.5 Excellent | — — | — — | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Curis Lifescien. Quarterly Performance
Latest quarterly metrics for CURIS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-4.77%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-31.66%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Curis Lifescien. Financial Statements
Annual income statement, balance sheet and cash flow for Curis Lifescien. (CURIS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Curis Lifescien.
About CURIS (Curis Lifescien.)
Curis Lifescien. (CURIS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ...market capitalisation of ₹82.62 (Cr). Curis Lifescien. has delivered a Return on Equity (ROE) of 21.80% and a ROCE of 21.25%. The debt-to-equity ratio stands at 0.46, reflecting the company's capital structure. Investors tracking CURIS share price can monitor key metrics including P/E ratio, promoter holding of 68.03%, and quarterly earnings growth.
Company Details
CURIS Share Price: Frequently Asked Questions
What is the current share price of Curis Lifescien.?
Curis Lifescien. (CURIS) trades at ₹102.20 on NSE. Market cap ₹82.62 (Cr). Educational data only.
What is the P/E ratio of Curis Lifescien.?
Curis Lifescien. has a P/E of 11.92x vs industry average 34.89x.
What is the Bull Run score for Curis Lifescien.?
Curis Lifescien. has a Bull Run score of 34.5/100 based on 25+ financial parameters.
Does Curis Lifescien. pay dividends?
Curis Lifescien. has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Curis Lifescien.?
Curis Lifescien. has ROE of 21.80%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Curis Lifescien.?
Curis Lifescien. has debt-to-equity of 0.46.
Is Curis Lifescien. a good investment?
Bull Run gives Curis Lifescien. a score of 34.5/100. This is not investment advice — consult a SEBI-registered advisor.